Ross Errington

Nov 11, 2024 | ondrugdelivery.com | Ross Errington |Simon Gardner

Citation: Errington R, Gardner S, “Reformulating pMDIS with Next-Generation Sustainable Propellants”. ONdrugDelivery, Issue 167 (Nov 2024), pp 38–41. Ross Errington and Simon Gardner discuss sustainability and the reformulation of pMDIs with low-GWP propellants.

Jan 5, 2024 | pharmaceuticalmanufacturer.media | Ross Errington |Jai McIntosh

New legislation and regulatory changes are causing shifts within the inhaled drug delivery market. By updating pressurised metered dose inhaler (pMDI) design and formulations, pharmaceutical companies can stay ahead in the changing market landscape. Ross Errington, Head of Drug Product Development at Recipharm, explores how evolving pMDIs can future-proof inhaled drug delivery. Inhaled drug delivery is growing rapidly.

Jan 3, 2024 | med-technews.com | Ross Errington

Ross Errington, head of drug product development at Recipharm, explores how evolving pMDIs can future-proof inhaled drug delivery. New legislation and regulatory changes are causing shifts within the inhaled drug delivery market. By updating pressurised metered dose inhaler (pMDI) design and formulations, pharmaceutical companies can stay ahead in the changing market landscape. Inhaled drug delivery is growing rapidly.

Nov 13, 2023 | ondrugdelivery.com | Ross Errington

Contact UsFrederick Furness Publishing LtdThe CandlemakersWest StreetLewes, BN7 2NZ United KingdomT: +44 (0) 1273 47 28 28E: [email protected]Company #: 8348388(Registered in England)VAT# : GB 153 0432 49Terms & Conditions | Privacy Policy

Nov 13, 2023 | ondrugdelivery.com | Ross Errington

Citation: Errington R, “Future-Proofing pMDI Design to Fit a Changing Market”. ONdrugDelivery, Issue 154 (Nov 2023), pp 34–36. Ross Errington explores how pharmaceutical companies can evolve their pMDI drug products to make them fit for the future considering the several recent regulatory changes that are transforming the landscape of inhalation drugs.